ARCHIVES

Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 34 No. 7 | July 29, 2011

Download PDF Visit The Full Archive

Related Articles

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

Women Who Received CMF Chemotherapy Score Lower On Cognitive Skill Exams

March 30, 2012

Wyden Asks Healy To Clarify CRADA Pricing Clause

January 3, 1992

Cooperative Group Chairmen, OPRR Seek Agreement On Assurances

January 6, 1984

Erbitux Addition to Chemotherapy Regimen Can Make Inoperable Disease Operable

April 26, 2013

In Brief: ACCC Meeting Move To Jan. 31 In Jacksonville; ACS Gynecologic Cancer Meeting Sept. 18-20 In Phila.

August 22, 1975